Unpacking the Latest Options Trading Trends in Johnson & Johnson

Investors with a lot of money to spend have taken a bearish stance on Johnson & Johnson JNJ.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with JNJ, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 8 uncommon options trades for Johnson & Johnson.

This isn't normal.

The overall sentiment of these big-money traders is split between 12% bullish and 87%, bearish.

Out of all of the special options we uncovered, 2 are puts, for a total amount of $117,800, and 6 are calls, for a total amount of $283,293.

Projected Price Targets

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $100.0 to $155.0 for Johnson & Johnson over the recent three months.

Insights into Volume & Open Interest

Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Johnson & Johnson's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Johnson & Johnson's whale trades within a strike price range from $100.0 to $155.0 in the last 30 days.

Johnson & Johnson 30-Day Option Volume & Interest Snapshot

Biggest Options Spotted:

About Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.

In light of the recent options history for Johnson & Johnson, it's now appropriate to focus on the company itself. We aim to explore its current performance.

Current Position of Johnson & Johnson

• Trading volume stands at 1,090,501, with JNJ's price down by -0.34%, positioned at $156.04.
• RSI indicators show the stock to be is currently neutral between overbought and oversold.
• Earnings announcement expected in 25 days.

What The Experts Say On Johnson & Johnson

In the last month, 4 experts released ratings on this stock with an average target price of $175.5.

• An analyst from RBC Capital has decided to maintain their Outperform rating on Johnson & Johnson, which currently sits at a price target of $181.
• An analyst from Wells Fargo has revised its rating downward to Equal-Weight, adjusting the price target to $163.
• Showing optimism, an analyst from UBS upgrades its rating to Buy with a revised price target of $180.
• An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $178.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Johnson & Johnson with Benzinga Pro for real-time alerts.